TGNA Stock Overview
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.57 |
| 52 Week High | €1.31 |
| 52 Week Low | €0.57 |
| Beta | 0.70 |
| 1 Month Change | -6.91% |
| 3 Month Change | -19.49% |
| 1 Year Change | -56.46% |
| 3 Year Change | -74.62% |
| 5 Year Change | -61.23% |
| Change since IPO | -98.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| TGNA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.8% | 0.5% |
| 1Y | -56.5% | -13.4% | 15.8% |
Return vs Industry: TGNA underperformed the German Biotechs industry which returned -13.7% over the past year.
Return vs Market: TGNA underperformed the German Market which returned 16.5% over the past year.
Price Volatility
| TGNA volatility | |
|---|---|
| TGNA Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: TGNA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TGNA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 144 | Alessandro Riva | www.transgene.fr |
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TGNA fundamental statistics | |
|---|---|
| Market cap | €74.15m |
| Earnings (TTM) | -€33.97m |
| Revenue (TTM) | €6.35m |
Is TGNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TGNA income statement (TTM) | |
|---|---|
| Revenue | €6.35m |
| Cost of Revenue | €34.28m |
| Gross Profit | -€27.92m |
| Other Expenses | €6.05m |
| Earnings | -€33.97m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 16, 2025
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -439.56% |
| Net Profit Margin | -534.72% |
| Debt/Equity Ratio | 68.3% |
How did TGNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 14:36 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgene SA is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |